Patient Gateway

RSS Feed

Deulorlatinib in ALK-Positive NSCLC: Can Deuteration Improve on Lorlatinib?

Lorlatinib After Five Years: TP53 and EML4::ALK Variant 3 Refine Prognosis but Do Not Define Benefit in ALK-Positive NSCLC

Chugai obtains Japanese approval for FoundationOne CDx Cancer Genomic Profile as a companion diagnostic of lorlatinib for ALK fusion gene-positive NSCLC

Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Lorlatinib for ALK Fusion Gene-Positive Non-Small Cell Lung Cancer

Adjuvant Alectinib Maintains Quality of Life During 2 Years of Treatment in Resected ALK-Positive NSCLC

Adjuvant Alectinib Maintains Quality of Life During 2 Years of Treatment in Resected ALK-Positive NSCLC

Correction: Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.